I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| pericyte | 6 studies | 34% ± 17% | |
| smooth muscle cell | 4 studies | 23% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| pericyte | 6 studies | 34% ± 17% | |
| smooth muscle cell | 4 studies | 23% ± 6% |
Insufficient scRNA-seq data for expression of ADRA2A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 99% | 3072.35 | 324 / 328 | 89% | 50.71 | 158 / 178 |
| breast | 100% | 6043.20 | 457 / 459 | 84% | 21.72 | 934 / 1118 |
| prostate | 96% | 1298.24 | 235 / 245 | 83% | 15.32 | 416 / 502 |
| ovary | 98% | 3158.73 | 177 / 180 | 61% | 12.26 | 264 / 430 |
| intestine | 84% | 1017.86 | 811 / 966 | 66% | 16.36 | 349 / 527 |
| uterus | 92% | 2092.51 | 156 / 170 | 41% | 7.28 | 190 / 459 |
| bladder | 95% | 2885.71 | 20 / 21 | 37% | 4.91 | 186 / 504 |
| thymus | 96% | 1758.26 | 630 / 653 | 32% | 3.32 | 192 / 605 |
| lung | 63% | 708.17 | 365 / 578 | 49% | 11.37 | 562 / 1155 |
| skin | 68% | 1144.45 | 1227 / 1809 | 39% | 5.49 | 186 / 472 |
| adipose | 100% | 7435.67 | 1201 / 1204 | 0% | 0 | 0 / 0 |
| stomach | 25% | 219.97 | 89 / 359 | 72% | 25.57 | 207 / 286 |
| spleen | 89% | 2570.30 | 214 / 241 | 0% | 0 | 0 / 0 |
| esophagus | 42% | 371.28 | 612 / 1445 | 44% | 16.65 | 81 / 183 |
| brain | 42% | 384.76 | 1103 / 2642 | 33% | 3.59 | 231 / 705 |
| adrenal gland | 23% | 158.94 | 59 / 258 | 50% | 14.23 | 114 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 72% | 11.75 | 21 / 29 |
| blood vessel | 66% | 906.81 | 875 / 1335 | 0% | 0 | 0 / 0 |
| kidney | 45% | 588.28 | 40 / 89 | 20% | 2.15 | 177 / 901 |
| tonsil | 0% | 0 | 0 / 0 | 44% | 6.32 | 20 / 45 |
| eye | 0% | 0 | 0 / 0 | 39% | 4.98 | 31 / 80 |
| liver | 4% | 19.90 | 8 / 226 | 20% | 3.09 | 80 / 406 |
| heart | 14% | 88.06 | 119 / 861 | 0% | 0 | 0 / 0 |
| muscle | 4% | 28.29 | 32 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_1901020 | Biological process | negative regulation of calcium ion transmembrane transporter activity |
| GO_0071881 | Biological process | adenylate cyclase-inhibiting adrenergic receptor signaling pathway |
| GO_0007265 | Biological process | Ras protein signal transduction |
| GO_0071880 | Biological process | adenylate cyclase-activating adrenergic receptor signaling pathway |
| GO_0032148 | Biological process | activation of protein kinase B activity |
| GO_0051044 | Biological process | positive regulation of membrane protein ectodomain proteolysis |
| GO_0019229 | Biological process | regulation of vasoconstriction |
| GO_0051926 | Biological process | negative regulation of calcium ion transport |
| GO_0035624 | Biological process | receptor transactivation |
| GO_0032870 | Biological process | cellular response to hormone stimulus |
| GO_0043410 | Biological process | positive regulation of MAPK cascade |
| GO_0006260 | Biological process | DNA replication |
| GO_0007565 | Biological process | female pregnancy |
| GO_0046676 | Biological process | negative regulation of insulin secretion |
| GO_0030168 | Biological process | platelet activation |
| GO_0043406 | Biological process | positive regulation of MAP kinase activity |
| GO_0042596 | Biological process | fear response |
| GO_0032147 | Biological process | activation of protein kinase activity |
| GO_0030036 | Biological process | actin cytoskeleton organization |
| GO_0070473 | Biological process | negative regulation of uterine smooth muscle contraction |
| GO_0045742 | Biological process | positive regulation of epidermal growth factor receptor signaling pathway |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0045955 | Biological process | negative regulation of calcium ion-dependent exocytosis |
| GO_0030335 | Biological process | positive regulation of cell migration |
| GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
| GO_0099171 | Biological process | presynaptic modulation of chemical synaptic transmission |
| GO_0050892 | Biological process | intestinal absorption |
| GO_0050955 | Biological process | thermoception |
| GO_0043268 | Biological process | positive regulation of potassium ion transport |
| GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
| GO_0050995 | Biological process | negative regulation of lipid catabolic process |
| GO_0007266 | Biological process | Rho protein signal transduction |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0061179 | Biological process | negative regulation of insulin secretion involved in cellular response to glucose stimulus |
| GO_0001819 | Biological process | positive regulation of cytokine production |
| GO_0071882 | Biological process | phospholipase C-activating adrenergic receptor signaling pathway |
| GO_0042311 | Biological process | vasodilation |
| GO_0071875 | Biological process | adrenergic receptor signaling pathway |
| GO_0032811 | Biological process | negative regulation of epinephrine secretion |
| GO_0042593 | Biological process | glucose homeostasis |
| GO_0010700 | Biological process | negative regulation of norepinephrine secretion |
| GO_0090303 | Biological process | positive regulation of wound healing |
| GO_0016323 | Cellular component | basolateral plasma membrane |
| GO_0098978 | Cellular component | glutamatergic synapse |
| GO_0098839 | Cellular component | postsynaptic density membrane |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0048787 | Cellular component | presynaptic active zone membrane |
| GO_0043679 | Cellular component | axon terminus |
| GO_0043025 | Cellular component | neuronal cell body |
| GO_0098691 | Cellular component | dopaminergic synapse |
| GO_0098982 | Cellular component | GABA-ergic synapse |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0031696 | Molecular function | alpha-2C adrenergic receptor binding |
| GO_0032795 | Molecular function | heterotrimeric G-protein binding |
| GO_0031996 | Molecular function | thioesterase binding |
| GO_0019901 | Molecular function | protein kinase binding |
| GO_0051380 | Molecular function | norepinephrine binding |
| GO_0051379 | Molecular function | epinephrine binding |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0031692 | Molecular function | alpha-1B adrenergic receptor binding |
| GO_0004938 | Molecular function | alpha2-adrenergic receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ADRA2A |
| Protein name | Alpha-2A adrenergic receptor (Alpha-2 adrenergic receptor subtype C10) (Alpha-2A adrenoreceptor) (Alpha-2A adrenoceptor) (Alpha-2AAR) |
| Synonyms | ADRAR ADRA2R |
| Description | FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol. . |
| Accessions | P08913 ENST00000280155.4 |
